Shilpa Medicare quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	466	321	+44.9%
EBITDA	136	91.6	+48.7%
EBITDA margin	29.3%	28.5%	+0.7 pts
Profit before tax	92.1	50.3	+83.0%
Net profit	101	46.9	+115.2%
EPS	₹5.16	₹4.79	+7.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	466	437	410	370	321	331	319	344	293	292	286	313	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	3.1	1.7	0.8	1.8	6.4	7.6	1.1	5.0	9.4	2.5	2.2	1.8
	469	439	411	372	328	338	320	349	302	294	289	315
	145	128	101	128	115	85.1	90.0	98.4	76.8	101	106	122
	8.5	7.0	7.1	7.4	4.2	6.6	6.7	6.0	2.8	5.4	3.8	4.8
	−17.8	7.4	25.4	−29.5	−39.6	12.7	−5.7	17.5	13.3	−9.4	−13.3	−1.0
	99.7	86.6	83.5	83.1	81.8	70.9	73.5	76.2	72.1	66.5	69.1	73.1
	12.1	13.7	10.7	15.7	18.8	14.5	11.7	25.6	23.7	24.2	26.2	23.2
	35.2	30.6	30.4	29.8	28.9	28.8	28.8	28.3	27.1	26.6	26.7	27.8
	94.7	88.7	78.6	73.1	68.4	78.6	74.1	59.6	54.0	58.1	55.0	53.8
	377	362	336	307	278	297	279	312	270	272	273	304
	136	120	114	108	91.6	76.8	80.7	86.0	73.6	70.1	65.9	60.3
	101	89.1	83.9	78.5	62.7	48.0	51.9	57.7	46.5	43.4	39.2	32.5
Profit
	92.1	77.1	74.1	64.5	50.3	41.1	41.3	37.2	32.2	21.7	15.2	11.1
	0.0	43.4	−12.9	0.0	0.0	−28.1	0.0	0.0	0.0	6.1	0.0	0.0
	92.1	120	61.2	64.5	50.3	13.0	41.3	37.2	32.2	27.9	15.2	11.1
	22.5	10.0	7.9	21.3	18.9	10.6	21.8	25.0	15.9	11.3	12.7	12.9
	−25.4	2.7	8.4	−0.9	−16.2	−9.9	−12.0	−6.1	−1.3	−8.0	−3.3	−5.3
	−2.8	12.7	16.3	20.4	2.7	0.8	9.8	18.8	14.6	3.2	9.5	7.6
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	0.0	0.0
	6.0	0.0	−0.4	−0.1	−0.7	2.3	0.3	−0.4	−3.5	−0.1	−1.1	−1.9
	101	108	44.6	44.1	46.9	14.5	31.8	17.9	14.1	24.5	4.7	1.6
	94.9	108	44.9	44.2	47.6	12.2	31.4	18.3	17.6	24.6	5.8	3.5
	0.0	0.0	4.2	−0.0	−0.0	−2.4	0.0	0.0	0.0	−2.4	−0.0	0.0
	101	108	48.8	44.0	46.9	12.1	31.8	18.0	14.1	22.1	4.7	1.6
	—	—	—	—	46.9	14.5	—	17.9	14.1	24.5	—	—
	—	—	0.0	—	0.0	0.0	−0.0	0.0	0.0	0.0	−0.1	0.0
Per share
	₹5.16	₹5.51	₹2.36	₹2.25	₹4.79	₹1.48	₹3.25	₹1.83	₹1.46	₹2.82	₹0.53	₹0.19
	₹5.16	₹5.51	₹2.36	₹2.25	₹4.79	₹1.48	₹3.25	₹1.83	₹1.46	₹2.82	₹0.53	₹0.19
Other comprehensive income — detail
	0.0	—	4.2	−0.0	−0.0	−2.4	—	—	—	—	—	—
	0.0	—	4.2	−0.0	—	−2.4	—	0.0	0.0	−3.5	—	0.0
	—	—	—	—	—	—	−0.0	0.0	0.0	−1.1	0.0	0.0
	0.0	—	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	—	0.0	0.0	0.0	0.0
	—	—	—	—	46.9	—	—	17.9	14.1	—	4.6	—
Per share — as-filed variants
	₹5.16	₹5.51	₹2.36	₹2.25	₹4.79	₹1.48	₹3.25	₹1.83	₹1.46	₹2.82	₹0.53	₹0.19
	₹5.16	₹5.51	₹2.36	₹2.25	₹4.79	₹1.48	₹3.25	₹1.83	₹1.46	₹2.82	₹0.53	₹0.19
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	331	295	276	264	242	226	228	222	200	195	190	187
	71.0%	67.5%	67.5%	71.5%	75.2%	68.4%	71.5%	64.5%	68.3%	66.7%	66.3%	59.8%
Adjusted (ex-exceptional items) — derived
	92.1	77.1	74.1	64.5	50.3	41.1	41.3	37.2	32.2	21.7	15.2	11.1
	0.0	43.4	−12.9	0.0	0.0	−28.1	0.0	0.0	0.0	6.1	0.0	0.0
	101	69.0	54.0	44.1	46.9	40.9	31.8	17.9	14.1	19.1	4.7	1.6
	₹5.16	₹3.53	₹2.86	₹2.25	₹4.79	₹4.18	₹3.25	₹1.83	₹1.46	₹2.20	₹0.53	₹0.19

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersNATCOPHARM SPARC STAR RUBICON SUPRIYA THYROCARE VIYASH PARKHOSPSMcap ₹18,300 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	313.0	286.5	291.7	292.5	343.8	319.3	330.8	321.5	370.0	409.7	437.0	465.8
Other Income	1.8	2.2	2.5	9.4	5.0	1.1	7.6	6.4	1.8	0.8	1.7	3.1
Total Income	314.8	288.7	294.2	302.0	348.8	320.4	338.4	327.8	371.7	410.5	438.7	468.9
Expenses
+ Cost of Materials Consumed	122.0	106.0	101.2	76.8	98.4	90.0	85.1	115.0	127.6	100.8	127.6	144.5
+ Purchases of Stock-in-Trade	4.8	3.8	5.4	2.8	6.0	6.7	6.6	4.2	7.4	7.1	7.0	8.5
+ Changes in Inventories	-1.0	-13.3	-9.4	13.3	17.5	-5.7	12.7	-39.6	-29.5	25.4	7.4	-17.8
+ Employee Benefit Expense	73.1	69.1	66.5	72.1	76.2	73.5	70.9	81.8	83.1	83.5	86.6	99.7
+ Finance Costs	23.2	26.2	24.2	23.7	25.6	11.7	14.5	18.8	15.7	10.7	13.7	12.1
+ Depreciation & Amortisation	27.8	26.7	26.6	27.1	28.3	28.8	28.8	28.9	29.8	30.4	30.6	35.2
+ Other Expenses	53.8	55.0	58.1	54.0	59.6	74.1	78.6	68.4	73.1	78.6	88.7	94.7
Total Expenses	303.7	273.5	272.5	269.8	311.6	279.2	297.3	277.5	307.2	336.5	361.6	376.8
EBITDA	60.3	65.9	70.1	73.6	86.0	80.7	76.8	91.6	108.3	114.3	119.7	136.3
EBIT	32.5	39.2	43.4	46.5	57.7	51.9	48.0	62.7	78.5	83.9	89.1	101.1
Profit
PBT before Exceptional Items	11.1	15.2	21.7	32.2	37.2	41.3	41.1	50.3	64.5	74.1	77.1	92.1
+ Exceptional Items	0.0	0.0	6.1	0.0	0.0	0.0	-28.1	0.0	0.0	-12.9	43.4	0.0
Pretax Income	11.1	15.2	27.9	32.2	37.2	41.3	13.0	50.3	64.5	61.2	120.5	92.1
+ Current Tax	12.9	12.7	11.3	15.9	25.0	21.8	10.6	18.9	21.3	7.9	10.0	22.5
+ Deferred Tax	-5.3	-3.3	-8.0	-1.3	-6.1	-12.0	-9.9	-16.2	-0.9	8.4	2.7	-25.4
Tax Expense	7.6	9.5	3.2	14.6	18.8	9.8	0.8	2.7	20.4	16.3	12.7	-2.8
+ Net Movement in Regulatory Deferral Balances	0.0	0.0	0.0	0.0	-0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Share of Associates & JVs	-1.9	-1.1	-0.1	-3.5	-0.4	0.3	2.3	-0.7	-0.1	-0.4	0.0	6.0
Net Income	1.6	4.7	24.5	14.1	17.9	31.8	14.5	46.9	44.1	44.6	107.8	100.9
+ Net Income — Continuing Ops	3.5	5.8	24.6	17.6	18.3	31.4	12.2	47.6	44.2	44.9	107.8	94.9
+ Other Comprehensive Income	0.0	-0.0	-2.4	0.0	0.0	0.0	-2.4	-0.0	-0.0	4.2	0.0	0.0
Total Comprehensive Income	1.6	4.7	22.1	14.1	18.0	31.8	12.1	46.9	44.0	48.8	107.8	100.9
Net Income to Common	—	—	24.5	14.1	17.9	—	14.5	46.9	—	—	—	—
Minority Interest	0.0	-0.1	0.0	0.0	0.0	-0.0	0.0	0.0	—	0.0	—	—
Per Share
Basic EPS	0.19	0.53	2.82	1.46	1.83	3.25	1.48	4.79	2.25	2.36	5.51	5.16
Diluted EPS	0.19	0.53	2.82	1.46	1.83	3.25	1.48	4.79	2.25	2.36	5.51	5.16
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.4	-0.0	-0.0	4.2	—	0.0
+ Items NOT to be Reclassified to P&L	0.0	—	-3.5	0.0	0.0	—	-2.4	—	-0.0	4.2	—	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	-1.1	0.0	0.0	-0.0	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	—	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.0	—	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	—	4.6	—	14.1	17.9	—	—	46.9	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.19	0.53	2.82	1.46	1.83	3.25	1.48	4.79	2.25	2.36	5.51	5.16
Diluted EPS — Continuing Operations	0.19	0.53	2.82	1.46	1.83	3.25	1.48	4.79	2.25	2.36	5.51	5.16
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	187.2	190.0	194.6	199.7	221.8	228.3	226.3	241.9	264.5	276.4	295.0	330.6
Gross Margin %	59.81	66.31	66.72	68.27	64.52	71.50	68.42	75.24	71.48	67.46	67.51	70.98
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	11.1	15.2	21.7	32.2	37.2	41.3	41.1	50.3	64.5	74.1	77.1	92.1
− Exceptional Items (reconciliation)	0.0	0.0	6.1	0.0	0.0	0.0	-28.1	0.0	0.0	-12.9	43.4	0.0
Net Income Adj (tax-effected)	1.6	4.7	19.1	14.1	17.9	31.8	40.9	46.9	44.1	54.0	69.0	100.9
EPS Adj	0.19	0.53	2.20	1.46	1.83	3.25	4.18	4.79	2.25	2.86	3.53	5.16
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	—
Paid Up Equity Capital	8.7	8.7	8.7	9.8	9.8	9.8	9.8	9.8	9.8	19.6	19.6	19.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Shilpa Medicare Q2 FY27 results date

Shilpa Medicare (NSE: SHILPAMED) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 29 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹101 crore, up 115.2% from ₹46.9 crore in Q1 FY26 and down 6.4% from ₹108 crore in Q4 FY26. Revenue from operations was ₹466 crore, up 44.9% year on year and up 6.6% from the previous quarter.

Board-meeting notice filed: 29 October 2026
Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 29 Oct
Q1 FY27 net profit: ₹101 Cr+115.2% vs Q1 FY26−6.4% vs Q4 FY26
Q1 FY27 revenue: ₹466 Cr+44.9% vs Q1 FY26+6.6% vs Q4 FY26
Q1 FY27 operating margin: 21.7%+2.2 pts vs Q1 FY26+1.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹44.1 CrRevenue ₹370 Cr
Q1 FY27 EPS (basic): ₹5.16

Questions

When will Shilpa Medicare announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 29 October 2026). Last year it reported Q2 FY26 on 13 November 2025.

What will Shilpa Medicare's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹44.1 crore and revenue from operations ₹370 crore. The latest quarter, Q1 FY27, had a net profit of ₹101 crore and revenue of ₹466 crore.

What were Shilpa Medicare's Q1 FY27 results?

Consolidated net profit was ₹101 crore, up 115.2% from ₹46.9 crore in Q1 FY26 and down 6.4% from ₹108 crore in Q4 FY26. Revenue from operations was ₹466 crore, up 44.9% year on year and up 6.6% from the previous quarter.

How has Shilpa Medicare's profit changed over the last four quarters?

Net profit by quarter: ₹44.1 crore in Q2 FY26, ₹44.6 crore in Q3 FY26, ₹108 crore in Q4 FY26 and ₹101 crore in Q1 FY27. That is ₹297 crore over the four quarters, up 167.6% from ₹111 crore in the four quarters before. Revenue from operations: ₹370 crore, ₹410 crore, ₹437 crore and ₹466 crore.

What was Shilpa Medicare's net profit in FY26?

Consolidated net profit was ₹243 crore in FY26 (April 2025–March 2026), up 210.8% from ₹78.3 crore in FY25. It was a profit of ₹31.9 crore in FY24 and a loss of ₹32.5 crore in FY23.

What was Shilpa Medicare's revenue in FY26?

Revenue from operations was ₹1,539 crore in FY26 (April 2025–March 2026), up 19.6% from ₹1,286 crore in FY25. It was ₹1,152 crore in FY24 and ₹1,050 crore in FY23: up 46.5% over three years, 13.6% a year on average.

Where do these Shilpa Medicare figures come from?

From Shilpa Medicare's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.